Tumor vaccine combined with oncolytic virus and neoantigen and preparation method thereof

Abstract

The invention discloses a tumor vaccine combined with oncolytic virus and neoantigen and its preparation method. The combined vaccine can be realized in two ways. The efficiency of reagents being phagocytized by antigen-presenting cells and increasing the number of T cells that can specifically recognize tumor neoantigens and tumor infiltration ability, thereby enhancing the anticancer effect; the second is to insert genes encoding tumor neoantigens into oncolytic virus vectors Among them, a large number of tumor neoantigens are expressed, combined with the tumor killing ability of oncolytic viruses, further enhance the local immune response of tumor lesions, increase the infiltration degree of killer T cells in tumor tissues, and cause local immunogenic responses and stimulate effects. The generation of cells achieves the anti-cancer effect; through experimental comparison, it is found that both the first combination vaccine and the second combination vaccine have good tumor-inhibiting effects, and the second combination vaccine has a significant tumor-inhibiting effect.

Description

technical field [0001] The invention relates to the field of genetic engineering, in particular to a tumor vaccine combined with an oncolytic virus and a neoantigen and a preparation method thereof. Background technique [0002] For a long time, finding effective ways to attack tumors has been the goal pursued by researchers. One of the biggest difficulties lies in the widespread heterogeneity of tumors. Not only within the tumor tissue, even within the same tumor type, there are great differences among different patients. During the rapid growth and proliferation of cancer cells, it is often too late to repair the errors that occur during DNA replication, so many new mutant proteins will appear, which are called neoantigens (Neoantigen). Early studies believed that the mutations carried by most tumor neoantigens had no effect on the growth of tumor cells and were negligible by-products. With the deepening of research, scientists have recently discovered that even if the m...

AI Technical Summary

Problems solved by technology

[0008] In order to solve the deficiencies in the prior art, the object of the present invention is to provide a tumor vaccine combined with oncolytic virus and neoantigen and its preparation method. The combined vaccine can be realized in two ways. The first is to use oncolytic The tumor killing of viral reagents produces a local immune response in tumor lesions, improves the phagocytosis efficiency of neoantigen polypeptide vaccines by antigen-presenting cells, and the number of T cells that can specifically recognize tumor neoantigens and tumor infiltration ability, thereby enhancing the anticancer effect The second is to insert the gene encoding tumor neoantigen into the oncolytic virus vector to improve the problem that the antigenic peptide cannot directly enter the tumor, and combine the tumor killing ability of the oncolytic virus to further enhance the local immune response of the tumor lesion. Increase the degree of infiltration of killer T cells in tumor tissue, generate local immunogenic responses, stimulate the production of effector cells, and transform "cold" tumors into "hot" tumors to achieve anti-cancer effects

Images